Protalix Biotherapeutics Inc (PLX)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $257.17M
Last updated: Nov 17, 2026 at 11:05 AM ET
Protalix Biotherapeutics Inc (PLX) Earnings: Report Dates and Results
Protalix Biotherapeutics (PLX) is expected to report earnings on Mar 16, 2027. In the quarter ended Sep 30, 2026, Protalix Biotherapeutics reported EPS of $0.05, above the -$0.02 estimate. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PLX has an expected report date of Mar 16, 2027.
PLX Earnings Call
The latest PLX earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 39 quarters below that had an estimate, PLX beat 18, missed 19 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $21.93M, up 22.9% from $17.85M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.05 | -$0.02 | -$0.05 - $0.01 | +350.00% | Beat | +66.7% | 2 | 0 up, 0 down | Nov 10, 2026 | $21.93M |
| Jun 30, 2026 | $0.05 | -$0.01 | -$0.03 - $0.01 | +600.00% | Beat | N/A | 2 | 0 up, 1 down | Aug 12, 2026 | $19.90M |
| Mar 31, 2026 | $0.22 | -$0.01 | -$0.01 - -$0.01 | N/A | N/A | N/A | 1 | 0 up, 1 down | May 13, 2026 | $33.75M |
| Dec 31, 2025 | -$0.07 | $0.04 | -$0.03 - $0.04 | -300.00% | Miss | -177.8% | 2 | 0 up, 1 down | Mar 18, 2026 | $9.12M |
| Sep 30, 2025 | $0.03 | $0.06 | $0.04 - $0.07 | -50.00% | Miss | 0.0% | 2 | 0 up, 1 down | Nov 13, 2025 | $17.85M |
| Jun 30, 2025 | -$0.04 | $0.03 | $0.02 - $0.04 | -233.33% | Miss | N/A | 2 | 0 up, 1 down | Aug 14, 2025 | $15.66M |
| Mar 31, 2025 | -$0.05 | $0.08 | N/A | -162.50% | Miss | N/A | N/A | 0 up, 0 down | May 9, 2025 | $10.11M |
| Dec 31, 2024 | $0.09 | $0.07 | N/A | +28.57% | Beat | N/A | N/A | 0 up, 0 down | Mar 17, 2025 | $18.22M |
| Sep 30, 2024 | $0.03 | $0.06 | N/A | -50.00% | Miss | N/A | 1 | 0 up, 0 down | Nov 14, 2024 | $17.96M |
| Jun 30, 2024 | -$0.03 | $0.02 | $0.02 - $0.02 | -250.00% | Miss | -114.3% | 1 | 0 up, 0 down | Aug 14, 2024 | $13.47M |
| Mar 31, 2024 | -$0.06 | -$0.02 | N/A | -200.00% | Miss | N/A | N/A | 0 up, 0 down | May 10, 2024 | $3.75M |
| Dec 31, 2023 | -$0.07 | -$0.03 | -$0.03 - -$0.03 | -133.33% | Miss | N/A | 1 | 0 up, 0 down | Mar 14, 2024 | $10.49M |
| Sep 30, 2023 | -$0.03 | -$0.07 | N/A | +57.14% | Beat | N/A | 1 | 0 up, 0 down | Nov 6, 2023 | $10.35M |
| Jun 30, 2023 | $0.21 | -$0.04 | -$0.04 - -$0.04 | +625.00% | Beat | N/A | 1 | 0 up, 0 down | Aug 7, 2023 | $35.08M |
| Mar 31, 2023 | -$0.05 | -$0.05 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | May 4, 2023 | $9.59M |
| Dec 31, 2022 | -$0.07 | -$0.15 | -$0.15 - -$0.15 | +53.33% | Beat | N/A | 1 | 0 up, 0 down | Feb 27, 2023 | $8.62M |
| Sep 30, 2022 | -$0.07 | -$0.15 | -$0.15 - -$0.15 | +53.33% | Beat | N/A | 1 | 0 up, 0 down | Nov 14, 2022 | $14.18M |
| Jun 30, 2022 | -$0.11 | -$0.18 | N/A | +38.89% | Beat | N/A | N/A | 0 up, 0 down | Aug 15, 2022 | $8.75M |
| Mar 31, 2022 | -$0.05 | -$0.04 | N/A | -25.00% | Miss | N/A | N/A | 0 up, 0 down | May 16, 2022 | $16.09M |
| Dec 31, 2021 | -$0.15 | -$0.11 | -$0.11 - -$0.11 | -36.36% | Miss | -1600.0% | 1 | N/A | Mar 31, 2022 | $8.55M |
| Sep 30, 2021 | -$0.09 | -$0.12 | N/A | +25.00% | Beat | N/A | N/A | N/A | Nov 15, 2021 | $12.05M |
| Jun 30, 2021 | -$0.25 | -$0.10 | N/A | -150.00% | Miss | N/A | 1 | N/A | Aug 16, 2021 | $6.43M |
| Mar 31, 2021 | -$0.14 | -$0.17 | -$0.17 - -$0.17 | +17.65% | Beat | -240.0% | 1 | N/A | May 14, 2021 | $11.32M |
| Dec 31, 2020 | $0.01 | -$0.08 | -$0.13 - -$0.04 | +112.50% | Beat | 0.0% | 2 | N/A | Mar 30, 2021 | $41.14M |
| Sep 30, 2020 | -$0.14 | -$0.08 | -$0.08 - -$0.08 | -75.00% | Miss | N/A | 1 | N/A | Oct 29, 2020 | $10.79M |
| Jun 30, 2020 | -$0.13 | -$0.20 | -$0.31 - -$0.10 | +35.00% | Beat | N/A | 2 | N/A | Aug 10, 2020 | $10.97M |
| Mar 31, 2020 | $0.10 | -$0.30 | -$0.30 - -$0.30 | +133.33% | Beat | N/A | 1 | N/A | Jun 1, 2020 | N/A |
| Dec 31, 2019 | $0.01 | -$0.63 | N/A | +101.59% | Beat | N/A | N/A | N/A | Mar 12, 2020 | $17.76M |
| Sep 30, 2019 | -$0.20 | -$0.35 | -$0.60 - -$0.10 | +42.86% | Beat | N/A | 2 | N/A | Nov 7, 2019 | $14.25M |
| Jun 30, 2019 | -$0.50 | -$0.30 | -$0.40 - -$0.20 | -66.67% | Miss | N/A | 2 | N/A | Aug 8, 2019 | $12.25M |
| Mar 31, 2019 | -$0.50 | -$0.25 | -$0.40 - -$0.10 | -100.00% | Miss | N/A | 2 | N/A | May 6, 2019 | $10.44M |
| Dec 31, 2018 | -$0.37 | -$0.45 | -$0.60 - -$0.30 | +17.78% | Beat | N/A | 2 | N/A | Mar 18, 2019 | N/A |
| Sep 30, 2018 | -$1.00 | -$0.40 | -$0.60 - -$0.20 | -150.00% | Miss | N/A | 2 | N/A | Nov 7, 2018 | $12.34M |
| Jun 30, 2018 | -$0.80 | -$0.40 | -$0.70 - -$0.40 | -100.00% | Miss | N/A | 2 | N/A | Aug 9, 2018 | $4.84M |
| Mar 31, 2018 | -$0.60 | -$0.90 | -$1.00 - -$0.80 | +33.33% | Beat | N/A | 2 | N/A | May 9, 2018 | $6.71M |
| Dec 31, 2017 | -$0.60 | -$0.60 | -$0.80 - -$0.40 | 0.00% | In line | N/A | 2 | N/A | Mar 6, 2018 | $4.30M |
| Sep 30, 2017 | -$0.90 | -$0.45 | N/A | -100.00% | Miss | N/A | 1 | N/A | Nov 8, 2017 | $7.53M |
| Jun 30, 2017 | -$1.08 | -$0.35 | -$0.60 - -$0.10 | -208.57% | Miss | N/A | 2 | N/A | Aug 9, 2017 | $6.36M |
| Mar 31, 2017 | -$0.50 | -$0.90 | -$1.00 - -$0.70 | +44.44% | Beat | N/A | 2 | N/A | May 10, 2017 | $2.89M |
| Dec 31, 2016 | -$1.27 | -$1.10 | N/A | -15.45% | Miss | -116.5% | N/A | N/A | Mar 16, 2017 | $2.08M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.13, after $0.03 the year before. It was -$3.97 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.13 | -533.3% |
| Dec 31, 2024 | $0.03 | N/A |
| Dec 31, 2023 | $0.06 | N/A |
| Dec 31, 2022 | -$0.30 | N/A |
| Dec 31, 2021 | -$0.63 | N/A |
| Dec 31, 2020 | -$0.16 | N/A |
| Dec 31, 2019 | -$1.19 | N/A |
| Dec 31, 2018 | -$2.77 | N/A |
| Dec 31, 2017 | -$3.08 | N/A |
| Dec 31, 2016 | -$3.97 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 1,900 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 1,850 | 6 | |
| 2025Q4 | Dec 31, 2025 | 2,718 | 6 | |
| 2025Q3 | Sep 30, 2025 | 3,459 | 7 | |
| 2025Q2 | Jun 30, 2025 | 2,974 | 7 | |
| 2025Q1 | Mar 31, 2025 | 3,562 | 7 | |
| 2024Q3 | Sep 30, 2024 | 3,147 | 8 | |
| 2024Q2 | Jun 30, 2024 | 3,275 | 6 |
2026Q1 Earnings Call
Opening remarks
Mike Moyer Investor Relations Thank you, operator, and welcome to the Protalix BioTherapeutics Q1 2026 Financial Results and Business Update Conference Call. With me today are Dror Bashan, President and CEO of Protalix; and Gilad Mamlok, Senior Vice President and Chief Financial Officer. A press release announcing the financial results and corporate updates was issued this morning and is available now on the Protalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release and this teleconference include forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in Protalix's filings with the U.S. Securities and Exchange Commission. I will now turn the call over to Mr. Bashan. Dror?
Dror Bashan President and CEO Thank you, Mike, and thank you, everyone, for joining our Q1 2026 financial results and business update call. I want to begin by highlighting two points that underscore the strength of our business today. First, during the quarter, we received a $25 million milestone from Chiesi, following the European Commission approval of Elfabrio's every 4-week dosing regimen. As a result, we ended the first quarter of this year with $51 million in cash, providing us with a strong balance sheet and substantial financial flexibility and sufficient funds to support our ongoing operations as well as our Phase II RELEASE study with PRX-115. Second, we are reaffirming our 2026 guidance. We continue to expect total revenue for the year to range from approximately $78 million to $83 million, inclusive of the $25 million milestone received from Chiesi. Within that outlook, we anticipate Elfabrio revenues, excluding milestones, of approximately $33 million to $35 million and Elelyso revenues of approximately $20 million to $23 million. Taken together, this guidance reflects the strength of our commercial partnerships and our confidence in execution across our business for the year ahead. We entered 2026 with good momentum with the regulatory progress for Elfabrio in Europe, which triggered a $25 million milestone payment, the continued enrollment of our PRX-115 Phase II RELEASE study and a growing focus on our rare renal disease preclinical pipeline. We remain confident in our strategy for the years ahead. Our partner, Chiesi, continues to execute well with Elfabrio across approved markets. Following the European Commission's recent approval of the every 4-week regimen, we believe Elfabrio is well positioned to meaningfully reduce treatment burden for eligible patients in the European Union without compromising efficacy. This added dosing flexibility strengthens Elfabrio's competitive position and supports broader adoption over time. In the United States, the FDA-approved dosing regimen remains unchanged.
Frequently Asked Questions About PLX
When is Protalix Biotherapeutics's next earnings date?
Protalix Biotherapeutics's next earnings report is expected for Mar 16, 2027.
Did PLX beat earnings estimates last quarter?
Yes. Protalix Biotherapeutics reported EPS of $0.05 for the quarter ended Sep 30, 2026, above the -$0.02 estimate, a 350.00% surprise.
What EPS do analysts expect from PLX next quarter?
The consensus EPS estimate for Protalix Biotherapeutics for the quarter ending Dec 31, 2026 is -$0.02 from 3 analysts, with estimates from -$0.04 to $0.01.
How often does PLX beat earnings estimates?
Protalix Biotherapeutics beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of +22.84%.
PLX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors